CSPC Pharma of Shijiazhuang has out-licensed global rights (ex-China) for a generic oncology drug to Watson Laboratories, a subsidiary of Allergan. Watson will pay up to $108 million in milestones, plus a profit-based royalty. The drug, which was not identified, was described as complex. CSPC will manufacture the drug, and Watson will be responsible for approvals in its own territories.
